Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) Stock Competitors & Peer Comparison
See SUVENPHAR.BO's competitors and their performance on the BSE and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for SUVENPHAR.BO and its BSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SUVENPHAR.BO | ₹1,075.30 | +0.00% | 411.4B | 98.29 | ₹10.94 | N/A |
| SUNPHARMA.NS | ₹1,941.10 | -0.66% | 4.7T | 37.71 | ₹51.48 | +0.82% |
| SUNPHARMA.BO | ₹1,941.00 | -0.67% | 4.7T | 38.06 | ₹51.00 | +0.82% |
| DIVISLAB.NS | ₹7,248.50 | -0.77% | 1.9T | 74.64 | ₹97.11 | +0.41% |
| DIVISLAB.BO | ₹7,246.65 | -0.77% | 1.9T | 71.63 | ₹101.17 | +0.41% |
| TORNTPHARM.NS | ₹4,961.50 | -2.05% | 1.7T | 74.34 | ₹66.74 | +0.77% |
| TORNTPHARM.BO | ₹4,959.80 | -2.09% | 1.7T | 75.26 | ₹65.90 | +0.77% |
| ZYDUSLIFE.NS | ₹1,108.70 | -0.46% | 1.1T | 23.04 | ₹48.13 | +0.09% |
| ZYDUSLIFE.BO | ₹1,108.90 | -0.42% | 1.1T | 23.13 | ₹47.94 | +0.09% |
| LUPIN.BO | ₹2,369.45 | -1.11% | 1.1T | 18.60 | ₹127.40 | +0.76% |
Stock Comparison
Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA.NS)
SUVENPHAR.BO vs SUNPHARMA.NS Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, SUNPHARMA.NS has a market cap of 4.7T. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while SUNPHARMA.NS trades at ₹1,941.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas SUNPHARMA.NS's P/E ratio is 37.71. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to SUNPHARMA.NS's ROE of +0.15%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to SUNPHARMA.NS. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check SUNPHARMA.NS's competition here
Sun Pharmaceutical Industries Limited (BSE: SUNPHARMA.BO)
SUVENPHAR.BO vs SUNPHARMA.BO Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, SUNPHARMA.BO has a market cap of 4.7T. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while SUNPHARMA.BO trades at ₹1,941.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas SUNPHARMA.BO's P/E ratio is 38.06. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to SUNPHARMA.BO's ROE of +0.15%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to SUNPHARMA.BO. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check SUNPHARMA.BO's competition here
Divi's Laboratories Limited (NSE: DIVISLAB.NS)
SUVENPHAR.BO vs DIVISLAB.NS Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, DIVISLAB.NS has a market cap of 1.9T. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while DIVISLAB.NS trades at ₹7,248.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas DIVISLAB.NS's P/E ratio is 74.64. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to DIVISLAB.NS's ROE of +0.16%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to DIVISLAB.NS. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check DIVISLAB.NS's competition here
Divi's Laboratories Limited (BSE: DIVISLAB.BO)
SUVENPHAR.BO vs DIVISLAB.BO Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, DIVISLAB.BO has a market cap of 1.9T. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while DIVISLAB.BO trades at ₹7,246.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas DIVISLAB.BO's P/E ratio is 71.63. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to DIVISLAB.BO's ROE of +0.16%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to DIVISLAB.BO. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check DIVISLAB.BO's competition here
Torrent Pharmaceuticals Limited (NSE: TORNTPHARM.NS)
SUVENPHAR.BO vs TORNTPHARM.NS Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, TORNTPHARM.NS has a market cap of 1.7T. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while TORNTPHARM.NS trades at ₹4,961.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas TORNTPHARM.NS's P/E ratio is 74.34. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to TORNTPHARM.NS's ROE of +0.26%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to TORNTPHARM.NS. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check TORNTPHARM.NS's competition here
Torrent Pharmaceuticals Limited (BSE: TORNTPHARM.BO)
SUVENPHAR.BO vs TORNTPHARM.BO Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, TORNTPHARM.BO has a market cap of 1.7T. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while TORNTPHARM.BO trades at ₹4,959.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas TORNTPHARM.BO's P/E ratio is 75.26. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to TORNTPHARM.BO's ROE of +0.26%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to TORNTPHARM.BO. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check TORNTPHARM.BO's competition here
Zydus Lifesciences Limited (NSE: ZYDUSLIFE.NS)
SUVENPHAR.BO vs ZYDUSLIFE.NS Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, ZYDUSLIFE.NS has a market cap of 1.1T. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while ZYDUSLIFE.NS trades at ₹1,108.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas ZYDUSLIFE.NS's P/E ratio is 23.04. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to ZYDUSLIFE.NS's ROE of +0.19%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to ZYDUSLIFE.NS. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check ZYDUSLIFE.NS's competition here
Zydus Lifesciences Limited (BSE: ZYDUSLIFE.BO)
SUVENPHAR.BO vs ZYDUSLIFE.BO Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, ZYDUSLIFE.BO has a market cap of 1.1T. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while ZYDUSLIFE.BO trades at ₹1,108.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas ZYDUSLIFE.BO's P/E ratio is 23.13. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to ZYDUSLIFE.BO's ROE of +0.19%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to ZYDUSLIFE.BO. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check ZYDUSLIFE.BO's competition here
Lupin Limited (BSE: LUPIN.BO)
SUVENPHAR.BO vs LUPIN.BO Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, LUPIN.BO has a market cap of 1.1T. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while LUPIN.BO trades at ₹2,369.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas LUPIN.BO's P/E ratio is 18.60. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to LUPIN.BO's ROE of +0.27%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to LUPIN.BO. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check LUPIN.BO's competition here
Lupin Limited (NSE: LUPIN.NS)
SUVENPHAR.BO vs LUPIN.NS Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, LUPIN.NS has a market cap of 1.1T. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while LUPIN.NS trades at ₹2,370.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas LUPIN.NS's P/E ratio is 18.61. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to LUPIN.NS's ROE of +0.27%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to LUPIN.NS. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check LUPIN.NS's competition here
Mankind Pharma Limited (NSE: MANKIND.NS)
SUVENPHAR.BO vs MANKIND.NS Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, MANKIND.NS has a market cap of 1T. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while MANKIND.NS trades at ₹2,507.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas MANKIND.NS's P/E ratio is 50.75. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to MANKIND.NS's ROE of +0.12%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to MANKIND.NS. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check MANKIND.NS's competition here
Mankind Pharma Limited (BSE: MANKIND.BO)
SUVENPHAR.BO vs MANKIND.BO Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, MANKIND.BO has a market cap of 1T. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while MANKIND.BO trades at ₹2,505.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas MANKIND.BO's P/E ratio is 51.05. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to MANKIND.BO's ROE of +0.12%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to MANKIND.BO. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check MANKIND.BO's competition here
Dr. Reddy's Laboratories Limited (NSE: DRREDDY.NS)
SUVENPHAR.BO vs DRREDDY.NS Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, DRREDDY.NS has a market cap of 971.1B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while DRREDDY.NS trades at ₹1,151.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas DRREDDY.NS's P/E ratio is 22.68. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to DRREDDY.NS's ROE of +0.09%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to DRREDDY.NS. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check DRREDDY.NS's competition here
Dr. Reddy's Laboratories Limited (BSE: DRREDDY.BO)
SUVENPHAR.BO vs DRREDDY.BO Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, DRREDDY.BO has a market cap of 971.1B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while DRREDDY.BO trades at ₹1,152.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas DRREDDY.BO's P/E ratio is 22.68. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to DRREDDY.BO's ROE of +0.09%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to DRREDDY.BO. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check DRREDDY.BO's competition here
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS)
SUVENPHAR.BO vs AUROPHARMA.NS Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, AUROPHARMA.NS has a market cap of 881.5B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while AUROPHARMA.NS trades at ₹1,532.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas AUROPHARMA.NS's P/E ratio is 25.39. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to AUROPHARMA.NS's ROE of +0.10%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to AUROPHARMA.NS. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check AUROPHARMA.NS's competition here
Aurobindo Pharma Limited (BSE: AUROPHARMA.BO)
SUVENPHAR.BO vs AUROPHARMA.BO Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, AUROPHARMA.BO has a market cap of 880.9B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while AUROPHARMA.BO trades at ₹1,531.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas AUROPHARMA.BO's P/E ratio is 25.38. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to AUROPHARMA.BO's ROE of +0.10%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to AUROPHARMA.BO. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check AUROPHARMA.BO's competition here
Laurus Labs Limited (NSE: LAURUSLABS.NS)
SUVENPHAR.BO vs LAURUSLABS.NS Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, LAURUSLABS.NS has a market cap of 865B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while LAURUSLABS.NS trades at ₹1,601.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas LAURUSLABS.NS's P/E ratio is 97.28. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to LAURUSLABS.NS's ROE of +0.18%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to LAURUSLABS.NS. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check LAURUSLABS.NS's competition here
Laurus Labs Limited (BSE: LAURUSLABS.BO)
SUVENPHAR.BO vs LAURUSLABS.BO Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, LAURUSLABS.BO has a market cap of 865B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while LAURUSLABS.BO trades at ₹1,602.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas LAURUSLABS.BO's P/E ratio is 96.93. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to LAURUSLABS.BO's ROE of +0.18%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to LAURUSLABS.BO. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check LAURUSLABS.BO's competition here
Alkem Laboratories Limited (BSE: ALKEM.BO)
SUVENPHAR.BO vs ALKEM.BO Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, ALKEM.BO has a market cap of 673.7B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while ALKEM.BO trades at ₹5,635.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas ALKEM.BO's P/E ratio is 29.26. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to ALKEM.BO's ROE of +0.17%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to ALKEM.BO. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check ALKEM.BO's competition here
Alkem Laboratories Limited (NSE: ALKEM.NS)
SUVENPHAR.BO vs ALKEM.NS Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, ALKEM.NS has a market cap of 673.6B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while ALKEM.NS trades at ₹5,633.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas ALKEM.NS's P/E ratio is 34.68. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to ALKEM.NS's ROE of +0.17%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to ALKEM.NS. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check ALKEM.NS's competition here
Glenmark Pharmaceuticals Limited (BSE: GLENMARK.BO)
SUVENPHAR.BO vs GLENMARK.BO Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, GLENMARK.BO has a market cap of 619B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while GLENMARK.BO trades at ₹2,193.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas GLENMARK.BO's P/E ratio is 45.47. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to GLENMARK.BO's ROE of +0.14%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to GLENMARK.BO. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check GLENMARK.BO's competition here
Glenmark Pharmaceuticals Limited (NSE: GLENMARK.NS)
SUVENPHAR.BO vs GLENMARK.NS Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, GLENMARK.NS has a market cap of 618.6B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while GLENMARK.NS trades at ₹2,192.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas GLENMARK.NS's P/E ratio is 35.93. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to GLENMARK.NS's ROE of +0.14%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to GLENMARK.NS. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check GLENMARK.NS's competition here
Ipca Laboratories Limited (BSE: IPCALAB.BO)
SUVENPHAR.BO vs IPCALAB.BO Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, IPCALAB.BO has a market cap of 447.3B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while IPCALAB.BO trades at ₹1,762.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas IPCALAB.BO's P/E ratio is 49.16. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to IPCALAB.BO's ROE of +0.14%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to IPCALAB.BO. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check IPCALAB.BO's competition here
Ipca Laboratories Limited (NSE: IPCALAB.NS)
SUVENPHAR.BO vs IPCALAB.NS Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, IPCALAB.NS has a market cap of 447.2B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while IPCALAB.NS trades at ₹1,762.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas IPCALAB.NS's P/E ratio is 38.10. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to IPCALAB.NS's ROE of +0.14%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to IPCALAB.NS. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check IPCALAB.NS's competition here
Ajanta Pharma Limited (NSE: AJANTPHARM.NS)
SUVENPHAR.BO vs AJANTPHARM.NS Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, AJANTPHARM.NS has a market cap of 421B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while AJANTPHARM.NS trades at ₹3,369.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas AJANTPHARM.NS's P/E ratio is 39.90. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to AJANTPHARM.NS's ROE of +0.25%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to AJANTPHARM.NS. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check AJANTPHARM.NS's competition here
Ajanta Pharma Limited (BSE: AJANTPHARM.BO)
SUVENPHAR.BO vs AJANTPHARM.BO Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, AJANTPHARM.BO has a market cap of 420.3B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while AJANTPHARM.BO trades at ₹3,366.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas AJANTPHARM.BO's P/E ratio is 39.87. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to AJANTPHARM.BO's ROE of +0.25%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to AJANTPHARM.BO. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check AJANTPHARM.BO's competition here
Suven Pharmaceuticals Limited (NSE: SUVENPHAR.NS)
SUVENPHAR.BO vs SUVENPHAR.NS Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, SUVENPHAR.NS has a market cap of 412.4B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while SUVENPHAR.NS trades at ₹1,078.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas SUVENPHAR.NS's P/E ratio is 98.90. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to SUVENPHAR.NS's ROE of +0.05%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to SUVENPHAR.NS. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check SUVENPHAR.NS's competition here
J. B. Chemicals & Pharmaceuticals Limited (NSE: JBCHEPHARM.NS)
SUVENPHAR.BO vs JBCHEPHARM.NS Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, JBCHEPHARM.NS has a market cap of 387.9B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while JBCHEPHARM.NS trades at ₹2,416.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas JBCHEPHARM.NS's P/E ratio is 52.07. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to JBCHEPHARM.NS's ROE of +0.19%. Regarding short-term risk, SUVENPHAR.BO is less volatile compared to JBCHEPHARM.NS. This indicates lower risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check JBCHEPHARM.NS's competition here
J. B. Chemicals & Pharmaceuticals Limited (BSE: JBCHEPHARM.BO)
SUVENPHAR.BO vs JBCHEPHARM.BO Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, JBCHEPHARM.BO has a market cap of 386.8B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while JBCHEPHARM.BO trades at ₹2,412.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas JBCHEPHARM.BO's P/E ratio is 52.61. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to JBCHEPHARM.BO's ROE of +0.19%. Regarding short-term risk, SUVENPHAR.BO is less volatile compared to JBCHEPHARM.BO. This indicates lower risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check JBCHEPHARM.BO's competition here
Emcure Pharmaceuticals Ltd. (NSE: EMCURE.NS)
SUVENPHAR.BO vs EMCURE.NS Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, EMCURE.NS has a market cap of 356.8B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while EMCURE.NS trades at ₹1,881.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas EMCURE.NS's P/E ratio is 70.98. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to EMCURE.NS's ROE of +0.20%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to EMCURE.NS. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check EMCURE.NS's competition here
Wockhardt Limited (BSE: WOCKPHARMA.BO)
SUVENPHAR.BO vs WOCKPHARMA.BO Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, WOCKPHARMA.BO has a market cap of 299.7B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while WOCKPHARMA.BO trades at ₹1,842.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas WOCKPHARMA.BO's P/E ratio is 140.50. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to WOCKPHARMA.BO's ROE of +0.04%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to WOCKPHARMA.BO. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check WOCKPHARMA.BO's competition here
Piramal Enterprises Limited (NSE: PEL.NS)
SUVENPHAR.BO vs PEL.NS Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, PEL.NS has a market cap of 254.9B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while PEL.NS trades at ₹1,124.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas PEL.NS's P/E ratio is 44.24. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to PEL.NS's ROE of +0.01%. Regarding short-term risk, SUVENPHAR.BO is less volatile compared to PEL.NS. This indicates lower risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check PEL.NS's competition here
Piramal Pharma Limited (BSE: PPLPHARMA.BO)
SUVENPHAR.BO vs PPLPHARMA.BO Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, PPLPHARMA.BO has a market cap of 240.6B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while PPLPHARMA.BO trades at ₹181.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas PPLPHARMA.BO's P/E ratio is -154.68. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to PPLPHARMA.BO's ROE of -0.04%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to PPLPHARMA.BO. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check PPLPHARMA.BO's competition here
Piramal Pharma Limited (NSE: PPLPHARMA.NS)
SUVENPHAR.BO vs PPLPHARMA.NS Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, PPLPHARMA.NS has a market cap of 240.5B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while PPLPHARMA.NS trades at ₹181.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas PPLPHARMA.NS's P/E ratio is -154.78. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to PPLPHARMA.NS's ROE of -0.04%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to PPLPHARMA.NS. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check PPLPHARMA.NS's competition here
Neuland Laboratories Limited (BSE: NEULANDLAB.BO)
SUVENPHAR.BO vs NEULANDLAB.BO Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, NEULANDLAB.BO has a market cap of 238.3B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while NEULANDLAB.BO trades at ₹18,570.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas NEULANDLAB.BO's P/E ratio is 64.24. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to NEULANDLAB.BO's ROE of +0.22%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to NEULANDLAB.BO. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check NEULANDLAB.BO's competition here
Neuland Laboratories Limited (NSE: NEULANDLAB.NS)
SUVENPHAR.BO vs NEULANDLAB.NS Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, NEULANDLAB.NS has a market cap of 237.9B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while NEULANDLAB.NS trades at ₹18,546.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas NEULANDLAB.NS's P/E ratio is 61.84. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to NEULANDLAB.NS's ROE of +0.22%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to NEULANDLAB.NS. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check NEULANDLAB.NS's competition here
Granules India Limited (NSE: GRANULES.NS)
SUVENPHAR.BO vs GRANULES.NS Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, GRANULES.NS has a market cap of 206.6B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while GRANULES.NS trades at ₹833.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas GRANULES.NS's P/E ratio is 33.56. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to GRANULES.NS's ROE of +0.16%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to GRANULES.NS. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check GRANULES.NS's competition here
Granules India Limited (BSE: GRANULES.BO)
SUVENPHAR.BO vs GRANULES.BO Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, GRANULES.BO has a market cap of 206.5B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while GRANULES.BO trades at ₹833.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas GRANULES.BO's P/E ratio is 33.55. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to GRANULES.BO's ROE of +0.16%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to GRANULES.BO. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check GRANULES.BO's competition here
AstraZeneca Pharma India Limited (NSE: ASTRAZEN.NS)
SUVENPHAR.BO vs ASTRAZEN.NS Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, ASTRAZEN.NS has a market cap of 200.1B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while ASTRAZEN.NS trades at ₹8,005.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas ASTRAZEN.NS's P/E ratio is 106.73. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to ASTRAZEN.NS's ROE of +0.23%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to ASTRAZEN.NS. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check ASTRAZEN.NS's competition here
AstraZeneca Pharma India Limited (BSE: ASTRAZEN.BO)
SUVENPHAR.BO vs ASTRAZEN.BO Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, ASTRAZEN.BO has a market cap of 200.1B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while ASTRAZEN.BO trades at ₹8,000.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas ASTRAZEN.BO's P/E ratio is 106.65. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to ASTRAZEN.BO's ROE of +0.23%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to ASTRAZEN.BO. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check ASTRAZEN.BO's competition here
Eris Lifesciences Limited (NSE: ERIS.NS)
SUVENPHAR.BO vs ERIS.NS Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, ERIS.NS has a market cap of 194.1B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while ERIS.NS trades at ₹1,400.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas ERIS.NS's P/E ratio is 39.62. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to ERIS.NS's ROE of +0.18%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to ERIS.NS. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check ERIS.NS's competition here
Eris Lifesciences Limited (BSE: ERIS.BO)
SUVENPHAR.BO vs ERIS.BO Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, ERIS.BO has a market cap of 194B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while ERIS.BO trades at ₹1,398.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas ERIS.BO's P/E ratio is 45.36. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to ERIS.BO's ROE of +0.18%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to ERIS.BO. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check ERIS.BO's competition here
Caplin Point Laboratories Limited (NSE: CAPLIPOINT.NS)
SUVENPHAR.BO vs CAPLIPOINT.NS Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, CAPLIPOINT.NS has a market cap of 187.5B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while CAPLIPOINT.NS trades at ₹2,467.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas CAPLIPOINT.NS's P/E ratio is 28.99. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to CAPLIPOINT.NS's ROE of +0.20%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to CAPLIPOINT.NS. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check CAPLIPOINT.NS's competition here
Caplin Point Laboratories Ltd. (BSE: CAPLIPOINT.BO)
SUVENPHAR.BO vs CAPLIPOINT.BO Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, CAPLIPOINT.BO has a market cap of 187.3B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while CAPLIPOINT.BO trades at ₹2,464.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas CAPLIPOINT.BO's P/E ratio is 32.80. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to CAPLIPOINT.BO's ROE of +0.20%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to CAPLIPOINT.BO. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check CAPLIPOINT.BO's competition here
Natco Pharma Limited (NSE: NATCOPHARM.NS)
SUVENPHAR.BO vs NATCOPHARM.NS Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, NATCOPHARM.NS has a market cap of 165B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while NATCOPHARM.NS trades at ₹921.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas NATCOPHARM.NS's P/E ratio is 12.45. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to NATCOPHARM.NS's ROE of +0.17%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to NATCOPHARM.NS. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check NATCOPHARM.NS's competition here
NATCO Pharma Limited (BSE: NATCOPHARM.BO)
SUVENPHAR.BO vs NATCOPHARM.BO Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, NATCOPHARM.BO has a market cap of 164.9B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while NATCOPHARM.BO trades at ₹920.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas NATCOPHARM.BO's P/E ratio is 12.42. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to NATCOPHARM.BO's ROE of +0.17%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to NATCOPHARM.BO. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check NATCOPHARM.BO's competition here
Cohance Lifesciences Limited (BSE: COHANCE.BO)
SUVENPHAR.BO vs COHANCE.BO Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, COHANCE.BO has a market cap of 159.6B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while COHANCE.BO trades at ₹417.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas COHANCE.BO's P/E ratio is 82.45. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to COHANCE.BO's ROE of +0.05%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to COHANCE.BO. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check COHANCE.BO's competition here
Cohance Lifesciences Limited (NSE: COHANCE.NS)
SUVENPHAR.BO vs COHANCE.NS Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, COHANCE.NS has a market cap of 159.6B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while COHANCE.NS trades at ₹417.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas COHANCE.NS's P/E ratio is 77.60. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to COHANCE.NS's ROE of +0.05%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to COHANCE.NS. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check COHANCE.NS's competition here
Alembic Pharmaceuticals Limited (BSE: APLLTD.BO)
SUVENPHAR.BO vs APLLTD.BO Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, APLLTD.BO has a market cap of 157.4B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while APLLTD.BO trades at ₹796.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas APLLTD.BO's P/E ratio is 21.24. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to APLLTD.BO's ROE of +0.13%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to APLLTD.BO. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check APLLTD.BO's competition here
Alembic Pharmaceuticals Limited (NSE: APLLTD.NS)
SUVENPHAR.BO vs APLLTD.NS Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, APLLTD.NS has a market cap of 156.8B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while APLLTD.NS trades at ₹797.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas APLLTD.NS's P/E ratio is 21.27. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to APLLTD.NS's ROE of +0.13%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to APLLTD.NS. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check APLLTD.NS's competition here
Jubilant Pharmova Limited (NSE: JUBLPHARMA.NS)
SUVENPHAR.BO vs JUBLPHARMA.NS Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, JUBLPHARMA.NS has a market cap of 152.9B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while JUBLPHARMA.NS trades at ₹965.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas JUBLPHARMA.NS's P/E ratio is 35.62. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to JUBLPHARMA.NS's ROE of +0.06%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to JUBLPHARMA.NS. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check JUBLPHARMA.NS's competition here
Jubilant Pharmova Limited (BSE: JUBLPHARMA.BO)
SUVENPHAR.BO vs JUBLPHARMA.BO Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, JUBLPHARMA.BO has a market cap of 152.9B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while JUBLPHARMA.BO trades at ₹962.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas JUBLPHARMA.BO's P/E ratio is 35.50. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to JUBLPHARMA.BO's ROE of +0.06%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to JUBLPHARMA.BO. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check JUBLPHARMA.BO's competition here
Alivus Life Sciences Limited (BSE: ALIVUS.BO)
SUVENPHAR.BO vs ALIVUS.BO Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, ALIVUS.BO has a market cap of 135.2B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while ALIVUS.BO trades at ₹1,101.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas ALIVUS.BO's P/E ratio is 24.51. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to ALIVUS.BO's ROE of +0.05%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to ALIVUS.BO. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check ALIVUS.BO's competition here
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS)
SUVENPHAR.BO vs ALIVUS.NS Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, ALIVUS.NS has a market cap of 135.2B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while ALIVUS.NS trades at ₹1,101.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas ALIVUS.NS's P/E ratio is 41.01. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to ALIVUS.NS's ROE of +0.18%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to ALIVUS.NS. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check ALIVUS.NS's competition here
Glenmark Life Sciences Limited (NSE: GLS.NS)
SUVENPHAR.BO vs GLS.NS Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, GLS.NS has a market cap of 133.1B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while GLS.NS trades at ₹1,086.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas GLS.NS's P/E ratio is 31.50. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to GLS.NS's ROE of +0.21%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to GLS.NS. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check GLS.NS's competition here
Glenmark Life Sciences Limited (BSE: GLS.BO)
SUVENPHAR.BO vs GLS.BO Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, GLS.BO has a market cap of 133B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while GLS.BO trades at ₹1,085.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas GLS.BO's P/E ratio is 30.23. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to GLS.BO's ROE of +0.21%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to GLS.BO. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check GLS.BO's competition here
Shilpa Medicare Limited (NSE: SHILPAMED.NS)
SUVENPHAR.BO vs SHILPAMED.NS Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, SHILPAMED.NS has a market cap of 118.6B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while SHILPAMED.NS trades at ₹606.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas SHILPAMED.NS's P/E ratio is 46.81. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to SHILPAMED.NS's ROE of +0.10%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to SHILPAMED.NS. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check SHILPAMED.NS's competition here
Procter & Gamble Health Limited (NSE: PGHL.NS)
SUVENPHAR.BO vs PGHL.NS Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, PGHL.NS has a market cap of 111.4B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while PGHL.NS trades at ₹6,714.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas PGHL.NS's P/E ratio is 34.10. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to PGHL.NS's ROE of +0.59%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to PGHL.NS. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check PGHL.NS's competition here
Procter & Gamble Health Limited (BSE: PGHL.BO)
SUVENPHAR.BO vs PGHL.BO Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, PGHL.BO has a market cap of 111.4B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while PGHL.BO trades at ₹6,723.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas PGHL.BO's P/E ratio is 37.26. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to PGHL.BO's ROE of +0.59%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to PGHL.BO. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check PGHL.BO's competition here
Viyash Scientific Limited (NSE: VIYASH.NS)
SUVENPHAR.BO vs VIYASH.NS Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, VIYASH.NS has a market cap of 109.5B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while VIYASH.NS trades at ₹250.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas VIYASH.NS's P/E ratio is 77.92. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to VIYASH.NS's ROE of +0.09%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to VIYASH.NS. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check VIYASH.NS's competition here
Caplin Point Laboratories Limited (BSE: CAPPL.BO)
SUVENPHAR.BO vs CAPPL.BO Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, CAPPL.BO has a market cap of 109.4B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while CAPPL.BO trades at ₹1,446.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas CAPPL.BO's P/E ratio is 50.30. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to CAPPL.BO's ROE of +0.10%. Regarding short-term risk, SUVENPHAR.BO is less volatile compared to CAPPL.BO. This indicates lower risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check CAPPL.BO's competition here
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS)
SUVENPHAR.BO vs AKUMS.NS Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, AKUMS.NS has a market cap of 105.2B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while AKUMS.NS trades at ₹687.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas AKUMS.NS's P/E ratio is 55.03. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to AKUMS.NS's ROE of +0.08%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to AKUMS.NS. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check AKUMS.NS's competition here
Strides Pharma Science Limited (NSE: STAR.NS)
SUVENPHAR.BO vs STAR.NS Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, STAR.NS has a market cap of 94B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while STAR.NS trades at ₹1,020.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas STAR.NS's P/E ratio is 16.92. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to STAR.NS's ROE of +0.20%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to STAR.NS. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check STAR.NS's competition here
Strides Pharma Science Limited (BSE: STAR.BO)
SUVENPHAR.BO vs STAR.BO Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, STAR.BO has a market cap of 93.8B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while STAR.BO trades at ₹1,019.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas STAR.BO's P/E ratio is 16.90. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to STAR.BO's ROE of +0.20%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to STAR.BO. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check STAR.BO's competition here
Sudeep Pharma Ltd. (NSE: SUDEEPPHRM.NS)
SUVENPHAR.BO vs SUDEEPPHRM.NS Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, SUDEEPPHRM.NS has a market cap of 93.2B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while SUDEEPPHRM.NS trades at ₹825.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas SUDEEPPHRM.NS's P/E ratio is 95.39. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to SUDEEPPHRM.NS's ROE of N/A. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to SUDEEPPHRM.NS. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check SUDEEPPHRM.NS's competition here
Suven Life Sciences Limited (BSE: SUVEN.BO)
SUVENPHAR.BO vs SUVEN.BO Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, SUVEN.BO has a market cap of 71.4B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while SUVEN.BO trades at ₹316.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas SUVEN.BO's P/E ratio is -25.49. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to SUVEN.BO's ROE of -0.87%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to SUVEN.BO. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check SUVEN.BO's competition here
Suven Life Sciences Limited (NSE: SUVEN.NS)
SUVENPHAR.BO vs SUVEN.NS Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, SUVEN.NS has a market cap of 71.3B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while SUVEN.NS trades at ₹316.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas SUVEN.NS's P/E ratio is -26.20. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to SUVEN.NS's ROE of -0.87%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to SUVEN.NS. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check SUVEN.NS's competition here
Sun Pharma Advanced Research Company Limited (BSE: SPARC.BO)
SUVENPHAR.BO vs SPARC.BO Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, SPARC.BO has a market cap of 70.2B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while SPARC.BO trades at ₹216.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas SPARC.BO's P/E ratio is 4.52. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to SPARC.BO's ROE of +14.36%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to SPARC.BO. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check SPARC.BO's competition here
Sun Pharma Advanced Research Company Limited (NSE: SPARC.NS)
SUVENPHAR.BO vs SPARC.NS Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, SPARC.NS has a market cap of 70.2B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while SPARC.NS trades at ₹216.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas SPARC.NS's P/E ratio is 4.52. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to SPARC.NS's ROE of +14.36%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to SPARC.NS. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check SPARC.NS's competition here
FDC Limited (NSE: FDC.NS)
SUVENPHAR.BO vs FDC.NS Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, FDC.NS has a market cap of 67.2B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while FDC.NS trades at ₹412.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas FDC.NS's P/E ratio is 26.76. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to FDC.NS's ROE of +0.12%. Regarding short-term risk, SUVENPHAR.BO is less volatile compared to FDC.NS. This indicates lower risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check FDC.NS's competition here
Aarti Pharmalabs Limited (NSE: AARTIPHARM.NS)
SUVENPHAR.BO vs AARTIPHARM.NS Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, AARTIPHARM.NS has a market cap of 61.1B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while AARTIPHARM.NS trades at ₹673.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas AARTIPHARM.NS's P/E ratio is 23.29. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to AARTIPHARM.NS's ROE of +0.09%. Regarding short-term risk, SUVENPHAR.BO is less volatile compared to AARTIPHARM.NS. This indicates lower risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check AARTIPHARM.NS's competition here
Aarti Pharmalabs Limited (BSE: AARTIPHARM.BO)
SUVENPHAR.BO vs AARTIPHARM.BO Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, AARTIPHARM.BO has a market cap of 61.1B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while AARTIPHARM.BO trades at ₹674.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas AARTIPHARM.BO's P/E ratio is 32.54. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to AARTIPHARM.BO's ROE of +0.09%. Regarding short-term risk, SUVENPHAR.BO is less volatile compared to AARTIPHARM.BO. This indicates lower risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check AARTIPHARM.BO's competition here
Shilpa Medicare Limited (BSE: SHILPAMED.BO)
SUVENPHAR.BO vs SHILPAMED.BO Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, SHILPAMED.BO has a market cap of 59.2B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while SHILPAMED.BO trades at ₹605.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas SHILPAMED.BO's P/E ratio is 48.65. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to SHILPAMED.BO's ROE of +0.10%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to SHILPAMED.BO. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check SHILPAMED.BO's competition here
Innova Captab Limited (NSE: INNOVACAP.NS)
SUVENPHAR.BO vs INNOVACAP.NS Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, INNOVACAP.NS has a market cap of 54.4B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while INNOVACAP.NS trades at ₹950.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas INNOVACAP.NS's P/E ratio is 44.69. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to INNOVACAP.NS's ROE of +0.14%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to INNOVACAP.NS. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check INNOVACAP.NS's competition here
Sequent Scientific Limited (BSE: SEQUENT.BO)
SUVENPHAR.BO vs SEQUENT.BO Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, SEQUENT.BO has a market cap of 50.6B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while SEQUENT.BO trades at ₹202.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas SEQUENT.BO's P/E ratio is 123.41. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to SEQUENT.BO's ROE of +0.09%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to SEQUENT.BO. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check SEQUENT.BO's competition here
Sequent Scientific Limited (NSE: SEQUENT.NS)
SUVENPHAR.BO vs SEQUENT.NS Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, SEQUENT.NS has a market cap of 50.6B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while SEQUENT.NS trades at ₹202.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas SEQUENT.NS's P/E ratio is 124.17. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to SEQUENT.NS's ROE of +0.09%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to SEQUENT.NS. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check SEQUENT.NS's competition here
Orchid Pharma Limited (NSE: ORCHPHARMA.NS)
SUVENPHAR.BO vs ORCHPHARMA.NS Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, ORCHPHARMA.NS has a market cap of 50.1B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while ORCHPHARMA.NS trades at ₹988.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas ORCHPHARMA.NS's P/E ratio is 159.45. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to ORCHPHARMA.NS's ROE of +0.02%. Regarding short-term risk, SUVENPHAR.BO is less volatile compared to ORCHPHARMA.NS. This indicates lower risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check ORCHPHARMA.NS's competition here
Orchid Pharma Limited (BSE: ORCHPHARMA.BO)
SUVENPHAR.BO vs ORCHPHARMA.BO Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, ORCHPHARMA.BO has a market cap of 50.1B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while ORCHPHARMA.BO trades at ₹987.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas ORCHPHARMA.BO's P/E ratio is 67.66. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to ORCHPHARMA.BO's ROE of +0.02%. Regarding short-term risk, SUVENPHAR.BO is less volatile compared to ORCHPHARMA.BO. This indicates lower risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check ORCHPHARMA.BO's competition here
Bliss GVS Pharma Limited (NSE: BLISSGVS.NS)
SUVENPHAR.BO vs BLISSGVS.NS Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, BLISSGVS.NS has a market cap of 49.3B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while BLISSGVS.NS trades at ₹464.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas BLISSGVS.NS's P/E ratio is 38.56. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to BLISSGVS.NS's ROE of +0.11%. Regarding short-term risk, SUVENPHAR.BO is less volatile compared to BLISSGVS.NS. This indicates lower risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check BLISSGVS.NS's competition here
Bliss GVS Pharma Limited (BSE: BLISSGVS.BO)
SUVENPHAR.BO vs BLISSGVS.BO Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, BLISSGVS.BO has a market cap of 49.1B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while BLISSGVS.BO trades at ₹463.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas BLISSGVS.BO's P/E ratio is 38.47. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to BLISSGVS.BO's ROE of +0.11%. Regarding short-term risk, SUVENPHAR.BO is less volatile compared to BLISSGVS.BO. This indicates lower risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check BLISSGVS.BO's competition here
RPG Life Sciences Limited (BSE: RPGLIFE.BO)
SUVENPHAR.BO vs RPGLIFE.BO Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, RPGLIFE.BO has a market cap of 48.7B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while RPGLIFE.BO trades at ₹2,913.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas RPGLIFE.BO's P/E ratio is 41.83. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to RPGLIFE.BO's ROE of +0.21%. Regarding short-term risk, SUVENPHAR.BO is less volatile compared to RPGLIFE.BO. This indicates lower risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check RPGLIFE.BO's competition here
RPG Life Sciences Limited (NSE: RPGLIFE.NS)
SUVENPHAR.BO vs RPGLIFE.NS Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, RPGLIFE.NS has a market cap of 48.6B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while RPGLIFE.NS trades at ₹2,937.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas RPGLIFE.NS's P/E ratio is 42.17. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to RPGLIFE.NS's ROE of +0.21%. Regarding short-term risk, SUVENPHAR.BO is less volatile compared to RPGLIFE.NS. This indicates lower risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check RPGLIFE.NS's competition here
IOL Chemicals and Pharmaceuticals Limited (BSE: IOLCP.BO)
SUVENPHAR.BO vs IOLCP.BO Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, IOLCP.BO has a market cap of 43.9B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while IOLCP.BO trades at ₹149.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas IOLCP.BO's P/E ratio is 29.29. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to IOLCP.BO's ROE of +0.08%. Regarding short-term risk, SUVENPHAR.BO is less volatile compared to IOLCP.BO. This indicates lower risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check IOLCP.BO's competition here
IOL Chemicals and Pharmaceuticals Limited (NSE: IOLCP.NS)
SUVENPHAR.BO vs IOLCP.NS Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, IOLCP.NS has a market cap of 43.8B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while IOLCP.NS trades at ₹149.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas IOLCP.NS's P/E ratio is 29.37. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to IOLCP.NS's ROE of +0.08%. Regarding short-term risk, SUVENPHAR.BO is less volatile compared to IOLCP.NS. This indicates lower risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check IOLCP.NS's competition here
Novartis India Limited (BSE: NOVARTIND.BO)
SUVENPHAR.BO vs NOVARTIND.BO Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, NOVARTIND.BO has a market cap of 40.7B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while NOVARTIND.BO trades at ₹1,647.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas NOVARTIND.BO's P/E ratio is 42.86. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to NOVARTIND.BO's ROE of +0.12%. Regarding short-term risk, SUVENPHAR.BO is less volatile compared to NOVARTIND.BO. This indicates lower risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check NOVARTIND.BO's competition here
Novartis India Limited (NSE: NOVARTIND.NS)
SUVENPHAR.BO vs NOVARTIND.NS Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, NOVARTIND.NS has a market cap of 40.1B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while NOVARTIND.NS trades at ₹1,641.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas NOVARTIND.NS's P/E ratio is 42.71. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to NOVARTIND.NS's ROE of +0.12%. Regarding short-term risk, SUVENPHAR.BO is less volatile compared to NOVARTIND.NS. This indicates lower risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check NOVARTIND.NS's competition here
Gujarat Themis Biosyn Ltd. (NSE: GUJTHEM.NS)
SUVENPHAR.BO vs GUJTHEM.NS Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, GUJTHEM.NS has a market cap of 39.3B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while GUJTHEM.NS trades at ₹360.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas GUJTHEM.NS's P/E ratio is 83.84. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to GUJTHEM.NS's ROE of +0.17%. Regarding short-term risk, SUVENPHAR.BO is less volatile compared to GUJTHEM.NS. This indicates lower risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check GUJTHEM.NS's competition here
Gufic Biosciences Limited (NSE: GUFICBIO.NS)
SUVENPHAR.BO vs GUFICBIO.NS Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, GUFICBIO.NS has a market cap of 38B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while GUFICBIO.NS trades at ₹378.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas GUFICBIO.NS's P/E ratio is 59.20. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to GUFICBIO.NS's ROE of +0.10%. Regarding short-term risk, SUVENPHAR.BO is less volatile compared to GUFICBIO.NS. This indicates lower risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check GUFICBIO.NS's competition here
Gufic Biosciences Limited (BSE: GUFICBIO.BO)
SUVENPHAR.BO vs GUFICBIO.BO Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, GUFICBIO.BO has a market cap of 38B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while GUFICBIO.BO trades at ₹378.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas GUFICBIO.BO's P/E ratio is 59.10. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to GUFICBIO.BO's ROE of +0.10%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to GUFICBIO.BO. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check GUFICBIO.BO's competition here
Unichem Laboratories Limited (NSE: UNICHEMLAB.NS)
SUVENPHAR.BO vs UNICHEMLAB.NS Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, UNICHEMLAB.NS has a market cap of 37.8B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while UNICHEMLAB.NS trades at ₹537.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas UNICHEMLAB.NS's P/E ratio is 14.96. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to UNICHEMLAB.NS's ROE of +0.10%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to UNICHEMLAB.NS. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check UNICHEMLAB.NS's competition here
Unichem Laboratories Limited (BSE: UNICHEMLAB.BO)
SUVENPHAR.BO vs UNICHEMLAB.BO Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, UNICHEMLAB.BO has a market cap of 37.8B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while UNICHEMLAB.BO trades at ₹539.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas UNICHEMLAB.BO's P/E ratio is 15.02. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to UNICHEMLAB.BO's ROE of +0.10%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to UNICHEMLAB.BO. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check UNICHEMLAB.BO's competition here
Aarti Drugs Limited (NSE: AARTIDRUGS.NS)
SUVENPHAR.BO vs AARTIDRUGS.NS Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, AARTIDRUGS.NS has a market cap of 36.9B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while AARTIDRUGS.NS trades at ₹404.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas AARTIDRUGS.NS's P/E ratio is 19.04. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to AARTIDRUGS.NS's ROE of +0.13%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to AARTIDRUGS.NS. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check AARTIDRUGS.NS's competition here
Aarti Drugs Limited (BSE: AARTIDRUGS.BO)
SUVENPHAR.BO vs AARTIDRUGS.BO Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, AARTIDRUGS.BO has a market cap of 36.9B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while AARTIDRUGS.BO trades at ₹404.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas AARTIDRUGS.BO's P/E ratio is 19.04. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to AARTIDRUGS.BO's ROE of +0.13%. Regarding short-term risk, SUVENPHAR.BO is more volatile compared to AARTIDRUGS.BO. This indicates higher risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check AARTIDRUGS.BO's competition here
Morepen Laboratories Limited (BSE: MOREPENLAB.BO)
SUVENPHAR.BO vs MOREPENLAB.BO Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, MOREPENLAB.BO has a market cap of 29.5B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while MOREPENLAB.BO trades at ₹53.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas MOREPENLAB.BO's P/E ratio is 31.09. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to MOREPENLAB.BO's ROE of +0.08%. Regarding short-term risk, SUVENPHAR.BO is less volatile compared to MOREPENLAB.BO. This indicates lower risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check MOREPENLAB.BO's competition here
Morepen Laboratories Limited (NSE: MOREPENLAB.NS)
SUVENPHAR.BO vs MOREPENLAB.NS Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, MOREPENLAB.NS has a market cap of 29.5B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while MOREPENLAB.NS trades at ₹53.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas MOREPENLAB.NS's P/E ratio is 28.62. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to MOREPENLAB.NS's ROE of +0.08%. Regarding short-term risk, SUVENPHAR.BO is less volatile compared to MOREPENLAB.NS. This indicates lower risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check MOREPENLAB.NS's competition here
Solara Active Pharma Sciences Limited (NSE: SOLARA.NS)
SUVENPHAR.BO vs SOLARA.NS Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, SOLARA.NS has a market cap of 23.7B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while SOLARA.NS trades at ₹491.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas SOLARA.NS's P/E ratio is 279.52. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to SOLARA.NS's ROE of -0.00%. Regarding short-term risk, SUVENPHAR.BO is less volatile compared to SOLARA.NS. This indicates lower risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check SOLARA.NS's competition here
Solara Active Pharma Sciences Limited (BSE: SOLARA.BO)
SUVENPHAR.BO vs SOLARA.BO Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, SOLARA.BO has a market cap of 23.7B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while SOLARA.BO trades at ₹490.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas SOLARA.BO's P/E ratio is 357.92. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to SOLARA.BO's ROE of -0.00%. Regarding short-term risk, SUVENPHAR.BO is less volatile compared to SOLARA.BO. This indicates lower risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check SOLARA.BO's competition here
Indoco Remedies Limited (NSE: INDOCO.NS)
SUVENPHAR.BO vs INDOCO.NS Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, INDOCO.NS has a market cap of 22.4B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while INDOCO.NS trades at ₹243.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas INDOCO.NS's P/E ratio is -17.30. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to INDOCO.NS's ROE of -0.10%. Regarding short-term risk, SUVENPHAR.BO is less volatile compared to INDOCO.NS. This indicates lower risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check INDOCO.NS's competition here
Indoco Remedies Limited (BSE: INDOCO.BO)
SUVENPHAR.BO vs INDOCO.BO Comparison July 2026
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.BO stands at 411.4B. In comparison, INDOCO.BO has a market cap of 22.4B. Regarding current trading prices, SUVENPHAR.BO is priced at ₹1,075.30 on the BSE, while INDOCO.BO trades at ₹242.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.BO currently has a P/E ratio of 98.29, whereas INDOCO.BO's P/E ratio is -23.26. In terms of profitability, SUVENPHAR.BO's ROE is +0.16%, compared to INDOCO.BO's ROE of -0.10%. Regarding short-term risk, SUVENPHAR.BO is less volatile compared to INDOCO.BO. This indicates lower risk in terms of short-term price fluctuations for SUVENPHAR.BO.Check INDOCO.BO's competition here